Research ExplorerPublicationsMulti tyrosine kinase inhibitor dasatinib as novel cause of ...

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Standard

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? / Hennigs, Jan K.; von Amsberg, Gunhild; Baumann, Hans Jörg; Honecker, Friedemann; Kluge, Stefan; Bokemeyer, Carsten; Brümmendorf, Tim; Klose, Hans.

In: BMC PULM MED, Vol. 11, 2011, p. 30.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hennigs, JK, von Amsberg, G, Baumann, HJ, Honecker, F, Kluge, S, Bokemeyer, C, Brümmendorf, T & Klose, H 2011, 'Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?', BMC PULM MED, vol. 11, pp. 30. https://doi.org/10.1186/1471-2466-11-30

APA

Hennigs, J. K., von Amsberg, G., Baumann, H. J., Honecker, F., Kluge, S., Bokemeyer, C., Brümmendorf, T., & Klose, H. (2011). Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC PULM MED, 11, 30. https://doi.org/10.1186/1471-2466-11-30

Vancouver

Hennigs JK, von Amsberg G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC PULM MED. 2011;11:30. https://doi.org/10.1186/1471-2466-11-30

Bibtex

@article{be68cc8343f448f4a0322efb27187d79,
title = "Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?",
abstract = "Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.",
keywords = "Humans, Male, Aged, Treatment Outcome, Hypertension, Pulmonary/*chemically induced/diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Protein Kinase Inhibitors/adverse effects/therapeutic use, Protein-Tyrosine Kinases/*antagonists & inhibitors, Pyrimidines/*adverse effects/therapeutic use, Thiazoles/*adverse effects/therapeutic use, Humans, Male, Aged, Treatment Outcome, Hypertension, Pulmonary/*chemically induced/diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Protein Kinase Inhibitors/adverse effects/therapeutic use, Protein-Tyrosine Kinases/*antagonists & inhibitors, Pyrimidines/*adverse effects/therapeutic use, Thiazoles/*adverse effects/therapeutic use",
author = "Hennigs, {Jan K.} and {von Amsberg}, Gunhild and Baumann, {Hans J{\"o}rg} and Friedemann Honecker and Stefan Kluge and Carsten Bokemeyer and Tim Br{\"u}mmendorf and Hans Klose",
year = "2011",
doi = "10.1186/1471-2466-11-30",
language = "English",
volume = "11",
pages = "30",
journal = "BMC PULM MED",
issn = "1471-2466",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

AU - Hennigs, Jan K.

AU - von Amsberg, Gunhild

AU - Baumann, Hans Jörg

AU - Honecker, Friedemann

AU - Kluge, Stefan

AU - Bokemeyer, Carsten

AU - Brümmendorf, Tim

AU - Klose, Hans

PY - 2011

Y1 - 2011

N2 - Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.

AB - Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.

KW - Humans

KW - Male

KW - Aged

KW - Treatment Outcome

KW - Hypertension, Pulmonary/chemically induced/diagnosis

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy

KW - Protein Kinase Inhibitors/adverse effects/therapeutic use

KW - Protein-Tyrosine Kinases/antagonists & inhibitors

KW - Pyrimidines/adverse effects/therapeutic use

KW - Thiazoles/adverse effects/therapeutic use

KW - Humans

KW - Male

KW - Aged

KW - Treatment Outcome

KW - Hypertension, Pulmonary/chemically induced/diagnosis

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy

KW - Protein Kinase Inhibitors/adverse effects/therapeutic use

KW - Protein-Tyrosine Kinases/antagonists & inhibitors

KW - Pyrimidines/adverse effects/therapeutic use

KW - Thiazoles/adverse effects/therapeutic use

U2 - 10.1186/1471-2466-11-30

DO - 10.1186/1471-2466-11-30

M3 - SCORING: Journal article

VL - 11

SP - 30

JO - BMC PULM MED

JF - BMC PULM MED

SN - 1471-2466

ER -